MS
Michael Shetzline
SVP, CMO, Head-Res&Drug

Michael Shetzline insider trades: Ironwood Pharmaceuticals (IRWD) stock sales

SVP, CMO, Head-Res&Drug, Ironwood Pharmaceuticals Last trade Feb 24, 2026 22 Form 4 filings
$122K
Sold, last 12 months
2 sales
$0
Bought, last 12 months
0 buys
12
Open-market trades
since 2021
1
Company
last trade 2026

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Michael reports to the SEC

Open-market buys and sales

12 trades reported on SEC Form 4, newest first

DateStockTypeValue
Feb 24, 2026IRWD↓ Sell$62K
Feb 23, 2026IRWD↓ Sell$59K
Feb 10, 2025IRWD↓ Sell$73K
May 20, 2024IRWD↓ Sell$104K
Feb 12, 2024IRWD↓ Sell$589K
May 22, 2023IRWD↓ Sell$104K
Feb 28, 2023IRWD↓ Sell$219K
May 23, 2022IRWD↓ Sell$122K
Feb 28, 2022IRWD↓ Sell$190K
Nov 23, 2021IRWD↓ Sell$160K
May 24, 2021IRWD↓ Sell$25K
Feb 26, 2021IRWD↓ Sell$40K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other IRWD insiders

Open-market trades in the last 12 months

About Michael Shetzline's insider trades

Michael Shetzline is SVP, CMO, Head-Res&Drug at Ironwood Pharmaceuticals (IRWD). Since Feb 26, 2021, Michael has reported no open-market purchases and 12 sales worth $1.7M on SEC Form 4. In the last 12 months: 2 sales ($122K).

Their filings also include grants and awards (12 filings), option exercises (1 filing). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every IRWD insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.